We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Platform Uses 3D Visualization to Reveal Disease Biomarkers in Multiomics Data

By LabMedica International staff writers
Posted on 28 Aug 2025

The ability to visualize health data in three dimensions can reveal patterns and relationships among predictive biomarkers that conventional methods cannot. More...

Biomarkers play a critical role in early diagnosis and personalized treatment, yet their complexity across multiomics data often makes analysis difficult. By introducing advanced visualization techniques, scientists can better interpret disease risks and treatment pathways in a more accessible and intuitive way. Now, researchers have developed an innovative solution to better visualize results produced by artificial intelligence/machine learning (AI/ML) approaches on integrated clinical and multi-omics data for novel biomarker discovery and predictive analysis.

3D IntelliGenes, developed by researchers at Rutgers University-New Brunswick (New Brunswick, NJ, USA), is an open-source AI/ML platform designed for multiomics data visualization. The software is optimized for standard desktops and available across Windows, macOS, and Linux, making it accessible to scientists from diverse bioinformatic backgrounds. It enables users to visually analyze large-scale biological and clinical datasets in a way that highlights subtle but important biomarker interactions.

In their study published in BMC Medical Research Methodology, the researchers have described the platform, representing the first detailed demonstration of how 3D visualization can integrate and interpret complex multiomics data. By building a comprehensive workflow, the researchers showed that the system can generate visual graphs mapping biomarker relationships, enabling scientists to detect disease-related signals more effectively than with standard approaches.

The platform’s applications extend well beyond research. It could support earlier diagnosis of diseases, improve the accuracy of biomarker discovery, and advance personalized medicine by tailoring treatments based on patient-specific molecular signatures. With further clinical integration, the technology could be adapted to detect disease indicators such as cardiovascular markers or cancer-specific changes, potentially influencing treatment strategies worldwide.

“Our goal is for multiomics data to become more accessible to the wider scientific community so researchers can better understand diseases and their treatments,” said Zeeshan Ahmed, who led the research team that developed 3D IntelliGenes. “For example, the software could produce visual graphs showing relationships between biomarkers, such as cardiovascular disease indicators, which could help researchers and clinicians analyze and interpret heart health and disease risks more effectively.”

Related Links:
Rutgers University-New Brunswick


New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Collection and Transport System
PurSafe Plus®
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
New
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Impaired vascular function in patients with chronic kidney disease (A K Grotle et al., Am J Physiol Renal Physiol (2025). DOI: 10.1152/ajprenal.00158.2025)

Kidney Disease Blood Marker Could Also Identify Cardiovascular Problems

Chronic kidney disease (CKD) affects millions worldwide and is strongly linked to cardiovascular complications rather than kidney failure itself. Patients with CKD often experience vascular dysfunction... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.